New RMAT Designations Include Autolous’ CAR-T, Direct Biologics’ Extracellular Vesicles And Allovir’s Antiviral T-cells

 
• By Bridget Silverman
  
FDA welcome mat for RMAT designees
• Source: Nielsen Hobbs; the Pink Sheet| Shutterstock images

More from US FDA Performance Tracker

More from Regulatory Trackers